1. Home
  2. ABUS vs GFR Comparison

ABUS vs GFR Comparison

Compare ABUS & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$3.74

Market Cap

836.0M

Sector

Health Care

ML Signal

N/A

Logo Greenfire Resources Ltd.

GFR

Greenfire Resources Ltd.

N/A

Current Price

$7.75

Market Cap

924.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ABUS
GFR
Founded
2005
2018
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
836.0M
924.7M
IPO Year
2008
2023

Fundamental Metrics

Financial Performance
Metric
ABUS
GFR
Price
$3.74
$7.75
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $7.91
AVG Volume (30 Days)
★ 2.3M
1.2M
Earning Date
11-20-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.26
N/A
EPS
★ 0.84
N/A
Revenue
★ $14,083,000.00
N/A
Revenue This Year
$1,208.75
N/A
Revenue Next Year
N/A
$78.80
P/E Ratio
$4.35
★ $4.33
Revenue Growth
★ 128.21
N/A
52 Week Low
$3.50
$4.15
52 Week High
$5.45
$7.16

Technical Indicators

Market Signals
Indicator
ABUS
GFR
Relative Strength Index (RSI) 32.13 65.65
Support Level $3.50 $5.59
Resistance Level $4.53 N/A
Average True Range (ATR) 0.18 0.31
MACD -0.04 -0.02
Stochastic Oscillator 15.82 97.29

Price Performance

Historical Comparison
ABUS
GFR

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations. The company is actively developing its Hangingstone Facilities using SAGD, an enhanced oil recovery extraction method.

Share on Social Networks: